Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CorMedix (CRMD) Shares Outstanding (Weighted Average) (2016 - 2025)

CorMedix has reported Shares Outstanding (Weighted Average) over the past 16 years, most recently at $72034.0 for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $72034.0 for Q4 2025, up 22.36% from a year ago — trailing twelve months through Dec 2025 was $72034.0 (up 22.36% YoY), and the annual figure for FY2025 was $72034.0, down 99.88%.
  • Shares Outstanding (Weighted Average) reached $72034.0 in Q4 2025 per CRMD's latest filing, down from $69.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $69.7 million in Q3 2025 and bottomed at $7.72 in Q3 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $42.2 million (2022), compared with a mean of $38.2 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) tumbled 100.0% in 2021 before it skyrocketed 514786881.87% in 2022.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $37.7 million in 2021, then rose by 6.92% to $40.3 million in 2022, then grew by 26.39% to $50.9 million in 2023, then tumbled by 99.88% to $58872.0 in 2024, then rose by 22.36% to $72034.0 in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CRMD at $72034.0 in Q4 2025, $69.7 million in Q3 2025, and $66.6 million in Q2 2025.